Syros Pharmaceuticals, Inc. SYRS is developing its pipeline candidate, tamibarotene, an oral, selective, retinoic acid receptor alpha or RARα agonist as a frontline treatment of acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (HR-MDS). The FDA granted a Fast Track designation to tamibarotene for the treatment of AML in April 2024. The regulatory body granted the prestigious tag to tamibarotene in combination with azacitidine and Roche RHHBY/AbbVie’s ABBV cancer drug Venclexta (venetoclax) for treating newly diagnosed AML with RARA gene overexpression in adult patients aged more than 75 years or who have comorbidities that preclude the use of intensive induction chemotherapy. This was one of the factors driving the stock’s rise in the said time frame. Shares of Syros have rallied 38.1% in the past three months compared with the industry’s increase of 10.8%. Zacks Investment Research Image Source: Zacks Investment Research The FDA had also previously granted a Fast Track designation to tamibarotene in combination with azacitidine for the treatment of adults with HR-MDS and RARA overexpression. The phase II SELECT-AML-1 study is currently evaluating tamibarotene in combination with Roche/AbbVie’s Venclexta and azacitidine in newly diagnosed patients with AML and RARA gene overexpression. The primary endpoint of the study is to check the complete response rate (CR)/complete response with incomplete hematologic recovery (Cri). Venclexta is being jointly commercialized by ABBV and RHHBY in the United States. Previously, initial data from the SELECT-AML-1 study showed that patients treated with the combo of tamibarotene plus Venclexta and azacytidine had a 100% CR/CRi rate compared with 70% for patients who were treated with Venclexta and azacytidine alone. Additional data from the SELECT-AML-1 study is expected later in the third quarter of 2024. The phase III SELECT-MDS-1 study is evaluating tamibarotene in combination with azacitidine in newly diagnosed patients with HR -MDS with RARA overexpression. Pivotal CR data from the study is expected by mid-fourth quarter of 2024. Syros is currently preparing for the new drug application for tamibarotene in HR-MDS. The company plans to establish tamibarotene as the new frontline standard of care for patients with HR-MDS with RARA overexpression. The two data readouts expected later in the year will be an important catalyst for the stock. Syros Pharmaceuticals, Inc. Price Syros Pharmaceuticals, Inc. Price Syros Pharmaceuticals, Inc. price | Syros Pharmaceuticals, Inc. Quote Zacks Rank & Stock to Consider Syros currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is ANI Pharmaceuticals, Inc. ANIP, carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. In the past 60 days, estimates for ANI Pharmaceuticals 2024 earnings per share have improved from $4.41 to $4.44. Earnings per share estimates for 2025 have improved from $4.85 to $5.42. Shares of ANIP have jumped 16.5% year to date. ANIP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 53.90%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Roche Holding AG (RHHBY):Free Stock Analysis Report AbbVie Inc. (ABBV):Free Stock Analysis Report ANI Pharmaceuticals, Inc. (ANIP):Free Stock Analysis Report Syros Pharmaceuticals, Inc. (SYRS):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...